Side-by-side · Research reference

Kisspeptin-10vsMOTS-c

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BAnimal-StrongHUMAN-REVIEWED16/68 cited

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

01Mechanism of Action

Parameter

Kisspeptin-10

MOTS-c

Primary target

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Pathway

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Downstream effect

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Feedback intact?

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Origin

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Antibody development

—

02Dosage Protocols

Parameter

Kisspeptin-10

MOTS-c

Clinical trial dose

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

—

Route

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

—

Evidence basis

Phase 1/2 trials

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Half-life

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

Standard dose

—

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

Frequency

—

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Lower / starter dose

—

2.5–5 mg / week

Recommended due to limited human data.

Duration

—

4–12 weeks (experimental)

Optimal cycle length unknown.

Reconstitution

—

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Timing

—

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

03Metabolic / Fat Loss Evidence

Parameter

Kisspeptin-10

MOTS-c

Primary fat target

—

Diet-induced / metabolic obesity; systemic fat utilization

Quantified reduction

—

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

IGF-1 impact

—

No direct IGF-1 pathway; AMPK-mediated

Effect on lean mass

—

High dose significantly ↑ lean mass in mice

Insulin sensitivity

—

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

Triglycerides

—

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

Glucose metabolism

—

Improved glucose tolerance; GLUT4 upregulationLee 2015

Effect reversibility

—

Unknown — no long-term follow-up data

Context dependency

—

No effect in normal-chow mice; requires metabolic stressReynolds 2021

Key publication

—

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

04Side Effects & Safety

Parameter

Kisspeptin-10

MOTS-c

Ovarian hyperstimulation

Theoretical risk with supraphysiological dosing in fertility protocols

—

Headache

Mild, reported in early-phase trials

—

Nausea

Transient GI symptoms with IV bolus

—

Hot flashes

Vasomotor symptoms from LH surge

—

Injection site reaction

Erythema, mild discomfort (SQ route)

Mild irritation (reported)

Fluid retention / Edema

—

Not reported

Glucose intolerance

—

Improves glucose toleranceLee 2015

Cardiovascular

—

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

Cancer risk

—

Contradictory data — some models suggest pro-proliferative effects

CNS / Neurological

—

Insomnia, headache (anecdotal reports)

GI symptoms

—

Nausea, stomach discomfort (reported)

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid — insufficient safety data

Evidence quality

—

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

Absolute Contraindications

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Relative Contraindications

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

05Administration Protocol

Parameter

Kisspeptin-10

MOTS-c

1. Reconstitution (if lyophilized)

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

2. Route selection

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

3. Timing

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

4. Monitoring

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

5. Storage

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

06Stack Synergy

Kisspeptin-10

— no documented stacks

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction